Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.57 |
| ▸ | HPGD | P15428 | 7/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.55 |
| ▸ | NPC1 | O15118 | 5/20 | 0.55 |
| ▸ | RAB9A | P51151 | 5/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | CASP3 | P42574 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.50 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.50 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31023872 | 1.00 | ALDH1A1 (0.57) | ALDH1A1HPGDSMN1; SMN2NPC1RAB9A | |
| SCHEMBL11177782 | 0.81 | HPGD (0.60) | ALDH1A1HPGDSMN1; SMN2NPC1RAB9A | |
| SCHEMBL31350706 | 0.80 | HPGD (0.53) | ALDH1A1HPGDSMN1; SMN2NPC1RAB9A | |
| SCHEMBL14149797 | 0.80 | ALDH1A1 (0.38) | ALDH1A1HPGDSMN1; SMN2NPC1RAB9A | |
| SCHEMBL3392697 | 0.79 | HPGD (0.69) | ALDH1A1HPGDSMN1; SMN2NPC1RAB9A | |
| SCHEMBL14184983 | 0.79 | HPGD (0.53) | ALDH1A1HPGDSMN1; SMN2NPC1RAB9A | |
| SCHEMBL11166104 | 0.77 | NPC1 (0.58) | ALDH1A1HPGDSMN1; SMN2NPC1RAB9A | |
| SCHEMBL1291283 | 0.77 | HPGD (0.50) | ALDH1A1HPGDSMN1; SMN2NPC1RAB9A | |
| SCHEMBL28552529 | 0.76 | HPGD (0.51) | ALDH1A1HPGDSMN1; SMN2NPC1RAB9A | |
| SCHEMBL8760144 | 0.76 | HPGD (0.68) | ALDH1A1HPGDSMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1846394-A1 | PYRAZOLYLAMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS | AstraZeneca AB (SE) | 2007-10-24 | — | — | EP | claimed |
| WO-2006082392-A1 | PYRAZOLYLAMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2006-08-10 | — | — | WO | claimed |
| EP-4566608-A2 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | Gilead Sciences, Inc. (US) | 2025-06-11 | — | — | EP | disclosed |
| US-20250179102-A1 | THERAPEUTICS COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. | 2025-06-05 | — | — | US | disclosed |
| EP-4445900-B1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES INC (US) | 2025-05-21 | — | — | EP | disclosed |
| EP-4440702-B1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES INC (US) | 2025-05-21 | — | — | EP | disclosed |
| US-20250042926-A1 | THERAPEUTIC COMPOUNDS FOR HIV | GILEAD SCIENCES, INC. | 2025-02-06 | — | — | US | disclosed |
| US-12187753-B2 | Therapeutics compounds for HIV virus infection | GILEAD SCIENCES, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| EP-4445900-A2 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | Gilead Sciences, Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| EP-4440702-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. (US) | 2024-10-09 | — | — | EP | disclosed |
| US-20240132527-A1 | THERAPEUTICS COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. | 2024-04-25 | — | — | US | disclosed |
| US-5002944-A | Compounds having cardiotonic activity | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1991-03-26 | — | — | US | disclosed |
| EP-0333727-A1 | HETEROCYCLIC SUBSTITUTED BICYCLOUREAS HAVING CARDIOTONIC ACTIVITY | RORER INTERNATIONAL (OVERSEAS) INC. (a Delaware corporation) (US) | 1989-09-27 | — | — | EP | disclosed |
| US-4859672-A | Pyrido[2,3-d]pyrimidinone and imidazo[4,5-b]pyrimidinone | RORER PHARMACEUTICAL CORPORATION (US) | 1989-08-22 | — | — | US | disclosed |
| WO-1988003025-A1 | HETEROCYCLIC SUBSTITUTED BICYCLOUREAS HAVING CARDIOTONIC ACTIVITY | RORER INTERNATIONAL (OVERSEAS) INC. (US) | 1988-05-05 | — | — | WO | disclosed |
| US-4350817-A | 4-Cl, Br or I-3-Carboxy or cyano-1,2-dihydro-2-oxo-1,8-naphthyridine derivatives | AMERICAN HOME PRODUCTS CORPORATION (US) | 1982-09-21 | — | — | US | disclosed |
| US-4347362-A | HYPOTENSIVE | AMERICAN HOME PRODUCTS CORPORATION (US) | 1982-08-31 | — | — | US | disclosed |
| US-4324893-A | 4-Amino-3-carboxy or cyano-1,2-dihydro-2-oxo-1,8-naphthyridine derivatives | AMERICAN HOME PRODUCTS CORPORATION (US) | 1982-04-13 | — | — | US | disclosed |
| EP-0018735-A1 | 1,8-Naphthyridine derivatives, their preparation, pharmaceutical compositions containing them | AMERICAN HOME PRODUCTS CORPORATION (US) | 1980-11-12 | — | — | EP | disclosed |
| WO-1980002287-A1 | 1,8-NAPHTHYRIDINE DERIVATIVES | AMERICAN HOME PROD (US) | 1980-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179102-A1 | THERAPEUTICS COMPOUNDS FOR HIV VIRUS INFECTION | CD4, HAVCR2, MAVS | ALDH1A1 1512/4885HPGD 1623/4885SMN1; SMN2 2972/4885 |
| US-20250042926-A1 | THERAPEUTIC COMPOUNDS FOR HIV | HAVCR2, CD4, MAVS | ALDH1A1 2001/4885HPGD 1254/4885SMN1; SMN2 2813/4885 |
| US-12187753-B2 | Therapeutics compounds for HIV virus infection | CD4, HAVCR2, MAVS | ALDH1A1 1512/4885HPGD 1623/4885SMN1; SMN2 2972/4885 |
| US-20240132527-A1 | THERAPEUTICS COMPOUNDS FOR HIV VIRUS INFECTION | CD4, HAVCR2, MAVS | ALDH1A1 1512/4885HPGD 1623/4885SMN1; SMN2 2972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.